Leonardo Rodrigues de Oliveira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leonardo Rodrigues de Oliveira has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Helio Moraes-Souza
Medical Clinical Department, Institute of Health Sciences, Federal University of Triângulo Mineiro, Uberaba, MG, Brazil
4 shared publications - Fernanda Bernadelli De Vito
Universidade Federal do Triângulo Mineiro
3 shared publications - Antônio Carlos Oliveira de Meneses
Universidade Federal do Triângulo Mineiro (UFTM), Uberaba, MG, Brazil
2 shared publications - Bruna Maria Bereta de Souza
Universidade Federal do Triângulo Mineiro
2 shared publications - Gualberto Ruas
Universidade Federal do Triângulo Mineiro
2 shared publications - Guilherme Rocha Pardi
Universidade Federal do Triângulo Mineiro
2 shared publications
Latest Publications
- Open Access
- 5 January 2026
- Published by Brazilian Journal of Implantology and Health Sciences in Periódicos Brasil. Pesquisa Científica
- Vol. 5 (1)
Identification of neoplastic cells in peripheral blood by flow cytometry in patients with B-cell non-Hodgkin's lymphoma
Introduction: Non-Hodgkin lymphoma (NHL) is the most common hematological neoplasm in the world (1). New techniques have been studied to allow for faster diagnosis of the disease, such as flow cytometry immunophenotyping (FCI). Methods: The possibility to identify the presence of circulating tumor cells (CTCs) in the peripheral blood of patients with NHL was attempted through FCI, and the findings were compared with the initial staging by bone marrow biopsy. Peripheral blood samples from nine patients with NHL were evaluated using a panel of monoclonal antibodies in order to detect B-cell chronic lymphoproliferative disorders. Results: Bone marrow biopsies and peripheral blood FCI were found to be discordant in three of the nine samples studied. Discordant cases were positive for neoplasia in peripheral blood immunophenotyping, and negative in immunohistochemical analysis of the bone marrow. In these three discordant cases, the tumor cells in the blood sample corresponded to less than 5% of the cellularity of the sample. Conclusion: Even though the use of peripheral blood remains poorly investigated regarding staging and monitoring of NHL, the findings of this study allowed us to define the importance of FCI in the early identification of neoplastic cells in patients with NHL.
- 5 January 2026
- Published by Brazilian Journal of Implantology and Health Sciences in Periódicos Brasil. Pesquisa Científica
- Vol. 5 (1)
Open AccessIdentification of neoplastic cells in peripheral blood by flow cytometry in patients with B-cell non-Hodgkin's lymphoma
Introduction: Non-Hodgkin lymphoma (NHL) is the most common hematological neoplasm in the world (1). New techniques have been studied to allow for faster diagnosis of the disease, such as flow cytometry immunophenotyping (FCI). Methods: The possibility to identify the presence of circulating tumor cells (CTCs) in the peripheral blood of patients with NHL was attempted through FCI, and the findings were compared with the initial staging by bone marrow biopsy. Peripheral blood samples from nine patients with NHL were evaluated using a panel of monoclonal antibodies in order to detect B-cell chronic lymphoproliferative disorders. Results: Bone marrow biopsies and peripheral blood FCI were found to be discordant in three of the nine samples studied. Discordant cases were positive for neoplasia in peripheral blood immunophenotyping, and negative in immunohistochemical analysis of the bone marrow. In these three discordant cases, the tumor cells in the blood sample corresponded to less than 5% of the cellularity of the sample. Conclusion: Even though the use of peripheral blood remains poorly investigated regarding staging and monitoring of NHL, the findings of this study allowed us to define the importance of FCI in the early identification of neoplastic cells in patients with NHL.
- Open Access
- 2 September 2025
- Published by Brazilian Journals in Cuadernos de Educación y Desarrollo
- Vol. 17 (9) , e9442
A utilização da Inteligência artificial no desenvolvimento de medicamentos para tratamento do câncer: uma revisão integrativa
Introdução: A inteligência artificial (IA) tem emergido como uma ferramenta inovadora no desenvolvimento de terapias anticâncer, otimizando a descoberta de novos medicamentos e a personalização do tratamento. Objetivo: Identificar evidências sobre a utilização da Inteligência artificial e avanços no desenvolvimento de medicamentos para tratamento do câncer. Metodologia: Trata-se de uma revisão integrativa baseada na seguinte pergunta norteadora: “Quais as evidências atuais sobre a utilização da Inteligência artificial no desenvolvimento de medicamentos para tratamento do câncer?”. O levantamento dos artigos foi realizado nas bases de dados: LILACS, através BVS-MS, MEDLINE, além da SciELO. As buscas foram realizadas com os Descritores DeCS/MeSH: “tratamento farmacológico”, “quimioterapia”, “inteligência artificial”, “neoplasias”, “câncer”. Resultados e discussão: Inicialmente foram recuperados 1.278 estudos, dos quais oito artigos foram selecionados com base em critérios de inclusão e exclusão. A IA demonstrou grande potencial na aceleração da descoberta de compostos, otimização de terapias combinadas e personalização do tratamento, especialmente por meio da triagem virtual e modelagem preditiva. Estudos destacaram sua eficácia na identificação de alvos terapêuticos e no design de fármacos, além de ajudar na previsão de interações moleculares. Considerações finais: A IA tem se mostrado essencial na inovação do tratamento do câncer, oferecendo novos métodos de desenvolvimento de terapias mais eficazes e com menos efeitos colaterais. No entanto, há necessidade de mais pesquisas empíricas e interdisciplinaridade para expandir suas aplicações clínicas.
- 2 September 2025
- Published by Brazilian Journals in Cuadernos de Educación y Desarrollo
- Vol. 17 (9) , e9442
Open AccessA utilização da Inteligência artificial no desenvolvimento de medicamentos para tratamento do câncer: uma revisão integrativa
Introdução: A inteligência artificial (IA) tem emergido como uma ferramenta inovadora no desenvolvimento de terapias anticâncer, otimizando a descoberta de novos medicamentos e a personalização do tratamento. Objetivo: Identificar evidências sobre a utilização da Inteligência artificial e avanços no desenvolvimento de medicamentos para tratamento do câncer. Metodologia: Trata-se de uma revisão integrativa baseada na seguinte pergunta norteadora: “Quais as evidências atuais sobre a utilização da Inteligência artificial no desenvolvimento de medicamentos para tratamento do câncer?”. O levantamento dos artigos foi realizado nas bases de dados: LILACS, através BVS-MS, MEDLINE, além da SciELO. As buscas foram realizadas com os Descritores DeCS/MeSH: “tratamento farmacológico”, “quimioterapia”, “inteligência artificial”, “neoplasias”, “câncer”. Resultados e discussão: Inicialmente foram recuperados 1.278 estudos, dos quais oito artigos foram selecionados com base em critérios de inclusão e exclusão. A IA demonstrou grande potencial na aceleração da descoberta de compostos, otimização de terapias combinadas e personalização do tratamento, especialmente por meio da triagem virtual e modelagem preditiva. Estudos destacaram sua eficácia na identificação de alvos terapêuticos e no design de fármacos, além de ajudar na previsão de interações moleculares. Considerações finais: A IA tem se mostrado essencial na inovação do tratamento do câncer, oferecendo novos métodos de desenvolvimento de terapias mais eficazes e com menos efeitos colaterais. No entanto, há necessidade de mais pesquisas empíricas e interdisciplinaridade para expandir suas aplicações clínicas.
- Open Access
- 28 December 2023
- Published by Revista Sociedade Científica in Revista Sociedade Científica
- Vol. 7 (1) , 1943-1951
Análise da demanda ventilatória em atividades de vida diária na insuficiência cardíaca com fração de ejeção normal durante quimioterapia de linfoma não Hodgkin.
O indivíduo quando é submetido ao tratamento quimioterápico pode sofrer diversas reações adversas dentre elas a cardiotoxicidade e pneumotoxicidade. Além disso, o tratamento pode provocar fadiga muscular que impacte na realização das atividades de vida diária. Relata-se o caso do paciente do sexo masculino, 50 anos de idade, com Linfoma não Hodgkin, foi submetido a avaliações cardíacas e pulmonares durante as atividades de vida diária pós-tratamento quimioterápico. Foram detectadas alterações importantes quanto à demanda ventilatória, força muscular respiratória, função pulmonar e função cardíaca com presença de insuficiência cardíaca com fração de ejeção normal.
- 28 December 2023
- Published by Revista Sociedade Científica in Revista Sociedade Científica
- Vol. 7 (1) , 1943-1951
Open AccessAnálise da demanda ventilatória em atividades de vida diária na insuficiência cardíaca com fração de ejeção normal durante quimioterapia de linfoma não Hodgkin.
O indivíduo quando é submetido ao tratamento quimioterápico pode sofrer diversas reações adversas dentre elas a cardiotoxicidade e pneumotoxicidade. Além disso, o tratamento pode provocar fadiga muscular que impacte na realização das atividades de vida diária. Relata-se o caso do paciente do sexo masculino, 50 anos de idade, com Linfoma não Hodgkin, foi submetido a avaliações cardíacas e pulmonares durante as atividades de vida diária pós-tratamento quimioterápico. Foram detectadas alterações importantes quanto à demanda ventilatória, força muscular respiratória, função pulmonar e função cardíaca com presença de insuficiência cardíaca com fração de ejeção normal.
- Open Access
- 17 October 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (14)
Perforin and granzyme B gene expression is associated with a short survival time in patients with multiple myeloma
Objectives: Perforin and granzyme B are essential proteins for protective immune responses mediated by Cytotoxic T Lymphocytes (CTLs) and Natural Killer cells (NK) against cancers, especially those of hematological origin. Our study investigated polymorphisms in the perforin gene (PRF1) and quantified the levels of the perforin and granzyme B proteins in patients with multiple myeloma (MM). Methods: The PRF1 coding region was evaluated in 58 patients with MM and 78 healthy individuals using direct sequencing. Quantitative real-time PCR was performed to quantify gene expression, and flow cytometry was used to determine the intracellular protein levels. Results: We did not observe differences in the allele frequencies of polymorphisms in the PRF1 gene as well as in perforin and granzyme B protein expression between patients with MM and healthy individuals. However, reduced expression of perforin or granzyme B genes was associated with a shorter survival time. In addition, patients with MM had significantly more CTLs expressing perforin and granzyme B, and had an increased number of NK cells. Conclusion: Our study suggests that the gene expression profile of perforin and granzyme B is a potential prognostic marker for MM.
- 17 October 2022
- Published by Research, Society and Development in Research, Society and Development
- Vol. 11 (14)
Open AccessPerforin and granzyme B gene expression is associated with a short survival time in patients with multiple myeloma
Objectives: Perforin and granzyme B are essential proteins for protective immune responses mediated by Cytotoxic T Lymphocytes (CTLs) and Natural Killer cells (NK) against cancers, especially those of hematological origin. Our study investigated polymorphisms in the perforin gene (PRF1) and quantified the levels of the perforin and granzyme B proteins in patients with multiple myeloma (MM). Methods: The PRF1 coding region was evaluated in 58 patients with MM and 78 healthy individuals using direct sequencing. Quantitative real-time PCR was performed to quantify gene expression, and flow cytometry was used to determine the intracellular protein levels. Results: We did not observe differences in the allele frequencies of polymorphisms in the PRF1 gene as well as in perforin and granzyme B protein expression between patients with MM and healthy individuals. However, reduced expression of perforin or granzyme B genes was associated with a shorter survival time. In addition, patients with MM had significantly more CTLs expressing perforin and granzyme B, and had an increased number of NK cells. Conclusion: Our study suggests that the gene expression profile of perforin and granzyme B is a potential prognostic marker for MM.
- Open Access
- 1 April 2022
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 44 (2) , 301-302
Reed-Sternberg and Hodgkin cells in bone marrow aspirate from a classical Hodgkin lymphoma patient
- 1 April 2022
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 44 (2) , 301-302
Open AccessReed-Sternberg and Hodgkin cells in bone marrow aspirate from a classical Hodgkin lymphoma patient
- Open Access
- 23 October 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (14)
Comparison of the use of Solidago chilensis (Arnica) and low-level laser therapy for the prevention of oral mucositis in patients submitted of head and neck radiotherapy and/or high toxicity chemotherapy
The oral mucositis is an adverse event of radiotherapy and/or high toxicity chemotherapy. The Solidago chilensis (Arnica) has been used for its antiseptic, analgesic, healing and anti-inflammatory properties. Objective: The purpose of this study was to evaluate the uses of Arnica for oral mucositis prevention in patients submitted to radiotherapy for head and neck tumors treatment and/or high toxicity chemotherapy. Methodology: The determination of the cytotoxicity index of the aqueous extract was determined in vitro. The oral mucosa was evaluated in days 0, 10 and 14 of patients in the groups: treated with lasertherapy (L, n=18), treated with Arnica (A, n=24) and, treated with lasertherapy associated with Arnica (LA, n=4). It was considered significant p<0.05. Results: It was determined IC50=90,74 μg/mL of Arnica’s aqueous extract in SCC-4 cells. The development of oral mucositis was associated with the type of treatment for oral mucositis prevention: L, A, and LA (χ2 = 24,72, p<0.0001). The level of oral mucositis had significant interaction with the type of prevention treatment [F(2) = 9.545, p<0.0001] and, within 14 days [F(2) = 11.995, p<0.0001]. Conclusions: The results obtained suggest which the use of Solidago chilensis (Arnica) can be an important therapeutic option for treatment with low-level laser therapy for oral mucositis prevention in patients submitted of head and neck radiotherapy and/or high toxicity chemotherapy.
- 23 October 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (14)
Open AccessComparison of the use of Solidago chilensis (Arnica) and low-level laser therapy for the prevention of oral mucositis in patients submitted of head and neck radiotherapy and/or high toxicity chemotherapy
The oral mucositis is an adverse event of radiotherapy and/or high toxicity chemotherapy. The Solidago chilensis (Arnica) has been used for its antiseptic, analgesic, healing and anti-inflammatory properties. Objective: The purpose of this study was to evaluate the uses of Arnica for oral mucositis prevention in patients submitted to radiotherapy for head and neck tumors treatment and/or high toxicity chemotherapy. Methodology: The determination of the cytotoxicity index of the aqueous extract was determined in vitro. The oral mucosa was evaluated in days 0, 10 and 14 of patients in the groups: treated with lasertherapy (L, n=18), treated with Arnica (A, n=24) and, treated with lasertherapy associated with Arnica (LA, n=4). It was considered significant p<0.05. Results: It was determined IC50=90,74 μg/mL of Arnica’s aqueous extract in SCC-4 cells. The development of oral mucositis was associated with the type of treatment for oral mucositis prevention: L, A, and LA (χ2 = 24,72, p<0.0001). The level of oral mucositis had significant interaction with the type of prevention treatment [F(2) = 9.545, p<0.0001] and, within 14 days [F(2) = 11.995, p<0.0001]. Conclusions: The results obtained suggest which the use of Solidago chilensis (Arnica) can be an important therapeutic option for treatment with low-level laser therapy for oral mucositis prevention in patients submitted of head and neck radiotherapy and/or high toxicity chemotherapy.
- Open Access
- 24 May 2021
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 44 (2) , 303-304
Megakaryocytes in pulmonary circulation: an “old” knowledge with new implications
- 24 May 2021
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 44 (2) , 303-304
Open AccessMegakaryocytes in pulmonary circulation: an “old” knowledge with new implications
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 54, e00102021
Dengue fever as a potential cause of sickle cell intrahepatic cholestasis: A report of two cases
Sickle cell intrahepatic cholestasis is a potentially fatal syndrome characterized by jaundice, painful hepatomegaly, and organ dysfunction. Two cases of sickle cell intrahepatic cholestasis associated with dengue fever were described. Endothelial damage/dysfunction is a mechanism involved in severe hepatobiliary complications related to sickle cell diseases. However, the reasons for the lack of increase in the admission of patients with sickle cell disease having severe acute hepatobiliary complications triggered by endothelial damage/dysfunction due to dengue fever remain unknown. This study describes the first association between sickle cell intrahepatic cholestasis and dengue fever.
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 54, e00102021
Open AccessDengue fever as a potential cause of sickle cell intrahepatic cholestasis: A report of two cases
Sickle cell intrahepatic cholestasis is a potentially fatal syndrome characterized by jaundice, painful hepatomegaly, and organ dysfunction. Two cases of sickle cell intrahepatic cholestasis associated with dengue fever were described. Endothelial damage/dysfunction is a mechanism involved in severe hepatobiliary complications related to sickle cell diseases. However, the reasons for the lack of increase in the admission of patients with sickle cell disease having severe acute hepatobiliary complications triggered by endothelial damage/dysfunction due to dengue fever remain unknown. This study describes the first association between sickle cell intrahepatic cholestasis and dengue fever.
- Open Access
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 54
Campylobacter fetus spondylodiscitis during immunochemotherapy for non-Hodgkin's lymphoma
- 1 January 2021
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 54
Open AccessCampylobacter fetus spondylodiscitis during immunochemotherapy for non-Hodgkin's lymphoma
- Open Access
- 31 December 2020
- Published by Universidade Tecnologica Federal do Parana (UTFPR) in Revista Brasileira de Qualidade de Vida
- Vol. 12 (4)
Efeitos dos treinamentos de alta e de baixa intensidade da musculatura inspiratória na qualidade de vida de indivíduos com doença pulmonar obstrutiva crônica (DPOC) grave e desnutridos
OBJETIVO: Analisar efeitos do treinamento da musculatura inspiratória (TMI) na qualidade de vida (QV) de indivíduos com doença pulmonar obstrutiva crônica (DPOC) grave e desnutridos.MÉTODOS: Trata-se de um estudo clínico randomizado, cego, controlado e longitudinal. Foram avaliados 32 homens, divididos igualmente em dois grupos: G1, submetido ao TMI de alta intensidade e, G2, submetido ao de baixa intensidade, ambos durante 12 semanas. Avaliações do grau de dispneia, prova de função pulmonar, pressão inspiratória máxima (PImáx), distância percorrida (DP), Saint George Respiratory Questionnaire (SGRQ) e mobilidade diafragmática (MD) foram realizadas no pré-TMI, na 12ª semana de treinamento e na 24ª semana pós-TMI.RESULTADOS: Após 12 semanas de TMI, G1 apresentou aumentos significativos de ventilação voluntária máxima (VVM), PImáx, DP e MD, além de diminuição na escala Medical Research Council modificada (MRCm) e das porcentagens do SGRQ, que se mantiveram após 12 semanas do encerramento do treinamento. G2 apresentou o mesmo comportamento do G1 em 12 semanas de treinamento, porém, na 24ª semana pós-TMI, os valores de VVM, MRCm e MD voltaram aos iniciais, de PImáx e DP apresentaram abaixo da avaliação inicial e das porcentagens do SGRQ aumentaram significantemente. Na análise intergrupo da 12ª semana, G1 apresentou valores maiores de VVM, PImáx, DP e MD e valores menores nas porcentagens do SGRQ do que G2. Na 24ª semana, G2 apresentou valores menores de VVM, PImáx, DP e MD e maiores de MRCm e das porcentagens do SGRQ do que G1.CONCLUSÕES: Tanto TMI de alta, quanto de baixa intensidade proporcionaram melhora da QV dos indivíduos com DPOC grave e desnutridos, mas somente o treinamento de alta intensidade apresentou efeitos benéficos a longo prazo.
- 31 December 2020
- Published by Universidade Tecnologica Federal do Parana (UTFPR) in Revista Brasileira de Qualidade de Vida
- Vol. 12 (4)
Open AccessEfeitos dos treinamentos de alta e de baixa intensidade da musculatura inspiratória na qualidade de vida de indivíduos com doença pulmonar obstrutiva crônica (DPOC) grave e desnutridos
OBJETIVO: Analisar efeitos do treinamento da musculatura inspiratória (TMI) na qualidade de vida (QV) de indivíduos com doença pulmonar obstrutiva crônica (DPOC) grave e desnutridos.MÉTODOS: Trata-se de um estudo clínico randomizado, cego, controlado e longitudinal. Foram avaliados 32 homens, divididos igualmente em dois grupos: G1, submetido ao TMI de alta intensidade e, G2, submetido ao de baixa intensidade, ambos durante 12 semanas. Avaliações do grau de dispneia, prova de função pulmonar, pressão inspiratória máxima (PImáx), distância percorrida (DP), Saint George Respiratory Questionnaire (SGRQ) e mobilidade diafragmática (MD) foram realizadas no pré-TMI, na 12ª semana de treinamento e na 24ª semana pós-TMI.RESULTADOS: Após 12 semanas de TMI, G1 apresentou aumentos significativos de ventilação voluntária máxima (VVM), PImáx, DP e MD, além de diminuição na escala Medical Research Council modificada (MRCm) e das porcentagens do SGRQ, que se mantiveram após 12 semanas do encerramento do treinamento. G2 apresentou o mesmo comportamento do G1 em 12 semanas de treinamento, porém, na 24ª semana pós-TMI, os valores de VVM, MRCm e MD voltaram aos iniciais, de PImáx e DP apresentaram abaixo da avaliação inicial e das porcentagens do SGRQ aumentaram significantemente. Na análise intergrupo da 12ª semana, G1 apresentou valores maiores de VVM, PImáx, DP e MD e valores menores nas porcentagens do SGRQ do que G2. Na 24ª semana, G2 apresentou valores menores de VVM, PImáx, DP e MD e maiores de MRCm e das porcentagens do SGRQ do que G1.CONCLUSÕES: Tanto TMI de alta, quanto de baixa intensidade proporcionaram melhora da QV dos indivíduos com DPOC grave e desnutridos, mas somente o treinamento de alta intensidade apresentou efeitos benéficos a longo prazo.